AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent - PubMed (original) (raw)
. 2003 Jun;305(3):1116-23.
doi: 10.1124/jpet.102.048132. Epub 2003 Mar 6.
Patricia K Somers, Charles Q Meng, Lee K Hoong, Ki-Ling Suen, Russell R Hill, Laura K Landers, Angela Chapman, Dustie Butteiger, Moira Jones, David Edwards, Alan Daugherty, Martin A Wasserman, R Wayne Alexander, Russell M Medford, Uday Saxena
Affiliations
- PMID: 12626663
- DOI: 10.1124/jpet.102.048132
AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent
Cynthia L Sundell et al. J Pharmacol Exp Ther. 2003 Jun.
Abstract
To explore the therapeutic efficacy and potential mechanisms of action of a new class of antiatherosclerotic drugs, AGI-1067 [mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester] (butanedioc acid) was tested in several animal models of atherosclerosis. AGI-1067, a novel phenolic antioxidant, was well tolerated in a 1-year study in hypercholesterolemic cynomolgus monkeys. It lowered low-density lipoprotein cholesterol (LDLc) by 41 and 90% at oral doses of 50 and 150 mg/kg, respectively and increased high-density lipoprotein cholesterol (HDLc) by 107% at the higher dose. In contrast, another phenolic antioxidant, probucol, had a modest LDLc-lowering effect (15% at 250 mg/kg) while decreasing HDLc (37% at 150 mg/kg). Histopathology of the aortas and coronary arteries revealed no atherosclerosis in the AGI-1067 (150 mg/kg) group and minimal-to-moderate atherosclerosis in the vehicle and probucol (150 mg/kg) groups. AGI-1067 also inhibited atherosclerosis in LDL receptor-deficient (LDLr -/-) mice and apolipoprotein E-deficient (ApoE -/-) mice even in the absence of a lipid-lowering effect. In LDLr -/- mice, AGI-1067 reduced aortic atherosclerosis by 49%. In ApoE -/- mice, AGI-1067 reduced atherosclerosis by 25, 41, and 49% in the arch, thoracic, and abdominal regions of the aorta. AGI-1067 also reduced vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1) mRNA levels in lungs of lipopolysaccharide-stimulated mice. At the cellular level, AGI-1067 inhibited tumor necrosis factor-alpha-inducible expression of VCAM-1, MCP-1, and E-selectin in human aortic endothelial cells (IC50 values = 6, 10, and 25 microM, respectively). These data show that AGI-1067 can inhibit atherosclerosis not only via its lipid-lowering effects but also by having direct anti-inflammatory effects on the vessel wall and suggest that it may be a novel therapeutic agent for coronary artery disease.
Similar articles
- Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent.
Kunsch C, Luchoomun J, Grey JY, Olliff LK, Saint LB, Arrendale RF, Wasserman MA, Saxena U, Medford RM. Kunsch C, et al. J Pharmacol Exp Ther. 2004 Mar;308(3):820-9. doi: 10.1124/jpet.103.059733. Epub 2003 Nov 14. J Pharmacol Exp Ther. 2004. PMID: 14617690 - AGIX-4207 [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acid], a novel antioxidant and anti-inflammatory compound: cellular and biochemical characterization of antioxidant activity and inhibition of redox-sensitive inflammatory gene expression.
Kunsch C, Luchoomun J, Chen XL, Dodd GL, Karu KS, Meng CQ, Marino EM, Olliff LK, Piper JD, Qiu FH, Sikorski JA, Somers PK, Suen KL, Thomas S, Whalen AM, Wasserman MA, Sundell CL. Kunsch C, et al. J Pharmacol Exp Ther. 2005 May;313(2):492-501. doi: 10.1124/jpet.104.080804. Epub 2005 Feb 8. J Pharmacol Exp Ther. 2005. PMID: 15701708 - AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Serebruany VL, Malinin A, Eisert C, Ong S. Serebruany VL, et al. Expert Rev Cardiovasc Ther. 2007 Jul;5(4):635-41. doi: 10.1586/14779072.5.4.635. Expert Rev Cardiovasc Ther. 2007. PMID: 17605642 Review. - Probucol [4,4'-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice.
Wu BJ, Di Girolamo N, Beck K, Hanratty CG, Choy K, Hou JY, Ward MR, Stocker R. Wu BJ, et al. J Pharmacol Exp Ther. 2007 May;321(2):477-84. doi: 10.1124/jpet.106.118612. Epub 2007 Feb 9. J Pharmacol Exp Ther. 2007. PMID: 17293560 - AGI-1067: a novel vascular protectant for prevention of restenosis.
Franks AM, Gardner SF. Franks AM, et al. Ann Pharmacother. 2006 Jan;40(1):66-73. doi: 10.1345/aph.1G142. Epub 2005 Nov 22. Ann Pharmacother. 2006. PMID: 16303986 Review.
Cited by
- Targeting endothelial vascular cell adhesion molecule-1 in atherosclerosis: drug discovery and development of vascular cell adhesion molecule-1-directed novel therapeutics.
Pickett JR, Wu Y, Zacchi LF, Ta HT. Pickett JR, et al. Cardiovasc Res. 2023 Oct 24;119(13):2278-2293. doi: 10.1093/cvr/cvad130. Cardiovasc Res. 2023. PMID: 37595265 Free PMC article. Review. - Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis.
Furuta K, Guo Q, Pavelko KD, Lee JH, Robertson KD, Nakao Y, Melek J, Shah VH, Hirsova P, Ibrahim SH. Furuta K, et al. J Clin Invest. 2021 Mar 15;131(6):e143690. doi: 10.1172/JCI143690. J Clin Invest. 2021. PMID: 33476308 Free PMC article. - Immunobiology of Atherosclerosis: A Complex Net of Interactions.
Herrero-Fernandez B, Gomez-Bris R, Somovilla-Crespo B, Gonzalez-Granado JM. Herrero-Fernandez B, et al. Int J Mol Sci. 2019 Oct 24;20(21):5293. doi: 10.3390/ijms20215293. Int J Mol Sci. 2019. PMID: 31653058 Free PMC article. Review. - Novel ASK1 inhibitor AGI-1067 improves AGE-induced cardiac dysfunction by inhibiting MKKs/p38 MAPK and NF-κB apoptotic signaling.
Liu Z, Zheng S, Wang X, Qiu C, Guo Y. Liu Z, et al. FEBS Open Bio. 2018 Aug 17;8(9):1445-1456. doi: 10.1002/2211-5463.12499. eCollection 2018 Sep. FEBS Open Bio. 2018. PMID: 30186746 Free PMC article. - Antioxidants in the Fight Against Atherosclerosis: Is This a Dead End?
Toledo-Ibelles P, Mas-Oliva J. Toledo-Ibelles P, et al. Curr Atheroscler Rep. 2018 May 21;20(7):36. doi: 10.1007/s11883-018-0737-7. Curr Atheroscler Rep. 2018. PMID: 29781062 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous